Health Disparities: A Foray into Race, Ethnicity, and Socioeconomic Status

By HEOR Staff Writer

January 31, 2024

Health Disparities Science

Introduction:

Health disparities, preventable health differences linked to social, economic, and environmental disadvantages, are a critical concern in modern healthcare. This article explores the pillars of health disparities science, namely race, ethnicity, and socioeconomic status (SES), and their impact on health outcomes.

Pillars of Health Disparities Science:

The first pillar, race and ethnicity, are treated as a social construct that significantly influences individuals’ lived experiences. These categorisations, based on phenotype, reflect the social hierarchy of access to power, wealth, and opportunity. Ethnicity, on the other hand, refers to broader cultural expressions in certain geographic regions.

The second pillar, SES, refers to individual, household, or family-based social and economic position. Lower SES is strongly linked with health outcomes, and contributes to health disparities through limited resources and opportunities to engage in health-promoting activities.

Minority Programs and Their Role:

In 1990, the National Institutes of Health (NIH) launched the Office of Minority Programs. This marked a significant move towards resolving health disparities. This initiative aimed to enhance upstream health determinants and reduce racial and ethnic differences in morbidity and mortality. Furthermore, in 2010, the mandate of the National Institute on Minority Health and Health Disparities (NIMHD) was to lead and coordinate research with all NIH entities. Their goal was to improve the health of all racial and ethnic minority groups and economically disadvantaged individuals. This emphasis on minority programs demonstrates a commitment to addressing health disparities at their source. It also highlights the importance of targeted, data-driven initiatives in health outcome improvement. 

Health Equity as an Aspirational Goal:

Health equity, the idea that everyone should have a fair opportunity to attain their full health potential, is an aspirational goal in health disparities science. It requires coordination among health systems, clinicians, patients, and communities. Moreover, it extends beyond reducing disparities to creating a health-related landscape that ensures everyone has access to the resources and opportunities necessary to achieve optimal health.

The Urgency of Focus in Health Disparities Science:

Despite the importance of other indicators of marginalisation and social determinants of health, health disparities research must remain focused on race and ethnicity and SES. It is critical to identify and address the specific mechanisms through which health disparities persist and to develop targeted interventions, higher-quality clinical care, and policies addressing the diverse needs within and across disadvantaged communities.

Reference url

Recent Posts

biologic dispensing implementation gaps
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care

By João L. Carapinha

July 7, 2026

Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...
curative therapy commercialization gap
Curative Therapy Commercialization Gap and Global Access Challenges

By João L. Carapinha

July 7, 2026

The curative therapy commercialization gap remains one of healthcare’s most stubborn contradictions: cell and gene therapies can deliver complete disease resolution, yet structural, financial, and infrastructural barriers keep them from reaching most patients who need them. This disconnect is esp...
transatlantic reference pricing innovation
Transatlantic Reference Pricing Innovation and Its Impact on Global Pharmaceutical Dynamics

By João L. Carapinha

July 7, 2026

The transatlantic reference pricing innovation is fundamentally altering pharmaceutical revenue expectations and patient access on both sides of the Atlantic. By anchoring U.S. reimbursement to the second-lowest net price among a basket of wealthy nations, the Most Favored Nation (MFN) policy cre...